Subject: CEO Honored as Hero in Opioid Crisis and Featured in Authority Magazine

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
CEO Honored as Hero in Opioid Crisis and Featured in Authority Magazine
Hot Stock to WatchHot Stock to Watch

Company: Progressive Care Inc. (OTCQB: RXMD)


Price: 0.06

Change (%): + 0.00 (0.00)

Volume: 38,238
RXMD Chart

Shital Mars CEO of Progressive Care Inc. Garners Coverage in Authority Magazine as a Hero of the Opioid Crisis

MIAMI, Jan. 10, 2019 (GLOBE NEWSWIRE) - Progressive Care Inc. (OTCQB: RXMD), a personalized healthcare services and technology company, today announced that it has garnered media coverage in Authority Magazine as a hero of the opioid crisis.

“I am honored to be recognized in Authority Magazine as a hero of the opioid crisis, something I am so passionate about fighting,” said S. Parikh Mars, CEO of Progressive Care Inc. “Progressive Care strives to put patients first by offering the best alternatives to opioid medications and by making the process to attain these medicines seamless and affordable.”

In an interview titled Heroes Of The Opioid Crisis, published December 27, 2018 in Authority Magazine Mars discusses how she would like to a see a bill that limits the extent to which a patient can be denied coverage for necessary medications.

In the piece, Mars writes: “We are fighting for non-opioid treatments for pain to be routinely covered by insurance. Today insurance companies are restricting benefits to the point where a patient can no longer get coverage for outpatient pain management solutions other than prescription grade ibuprofen, or Tylenol. There are also many plans that will cover the opioid treatment after Tylenol has been tried, but not cover a similar in cost non-opioid treatment. This needs to change. We need to recognize that pain is subjective and no two pain patients are the same. We need to have all of the options available to treat patients with pain and cost needs to stop being the primary concern.”

Continue Reading

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks